Venetoclax for chronic lymphocytic leukemia associated immune thrombocytopenia following recovery from progressive multifocal leukoencephalopathy

Leuk Res. 2020 Aug:95:106390. doi: 10.1016/j.leukres.2020.106390. Epub 2020 May 26.

Authors

N O'Connor-Byrne¹, J Quinn², S V Glavey³, M Lavin⁴, F Brett⁵, P T Murphy⁵

Affiliations

¹ Beaumont Hospital, Ireland. Electronic address: [email protected].
² Beaumont Hospital, Ireland; Department of Medicine, Royal College of Surgeons in Ireland, Ireland.
³ Beaumont Hospital, Ireland; Department of Molecular Medicine, Royal College of Surgeons in Ireland, Ireland.
⁴ Beaumont Hospital, Ireland; Irish Centre of Vascular Biology, Ireland.
⁵ Beaumont Hospital, Ireland.

PMID: 32526595
DOI: 10.1016/j.leukres.2020.106390

No abstract available

Publication types

Letter
Comment

MeSH terms

Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / complications
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Leukoencephalopathy, Progressive Multifocal* / chemically induced
Leukoencephalopathy, Progressive Multifocal* / drug therapy
Purpura, Thrombocytopenic, Idiopathic* / drug therapy
Sulfonamides

Substances

Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
venetoclax